End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -6.96% | -9.26% | -57.76% |
Valuation
Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 5.174 | 1.164 | 2.991 | - | - |
Enterprise Value (EV) 1 | 3.789 | 1.164 | 2.991 | 2.991 | 2.991 |
P/E ratio | -0.69 x | -0.37 x | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -7,15,778 x | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 8.26 | 398 | 2,240 | - | - |
Reference price 2 | 626.7 | 2.927 | 1.335 | 1.335 | 1.335 |
Announcement Date | 16/04/20 | 10/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | -7.228 | - | - | - | - |
EBIT 1 | -7.259 | - | -7.846 | -10.29 | -12.76 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | -6.826 | - | - | - | - |
Net income | -6.632 | -3.869 | - | - | - |
Net margin | - | - | - | - | - |
EPS | -912.0 | -7.880 | - | - | - |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 16/04/20 | 10/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT | -3.152 | - | - | - | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -3.028 | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | -248.0 | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 16/04/20 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | 1.38 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | 3.02 | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 16/04/20 | 10/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-57.76% | 3.29M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- CYTO Stock
- Financials Altamira Therapeutics Ltd.